Free Trial

Valneva (VALN) Competitors

Valneva logo
$8.94 -0.24 (-2.61%)
As of 04:00 PM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

VALN vs. MOR, HCM, BHC, OGN, KNSA, GMTX, CGON, ALVO, CPRX, and TARS

Should you be buying Valneva stock or one of its competitors? The main competitors of Valneva include MorphoSys (MOR), HUTCHMED (HCM), Bausch Health Cos (BHC), Organon & Co. (OGN), Kiniksa Pharmaceuticals International (KNSA), Gemini Therapeutics (GMTX), CG Oncology (CGON), Alvotech (ALVO), Catalyst Pharmaceuticals (CPRX), and Tarsus Pharmaceuticals (TARS). These companies are all part of the "pharmaceutical products" industry.

Valneva vs. Its Competitors

MorphoSys (NASDAQ:MOR) and Valneva (NASDAQ:VALN) are both medical companies, but which is the better stock? We will compare the two companies based on the strength of their profitability, analyst recommendations, dividends, media sentiment, institutional ownership, earnings, risk and valuation.

Valneva has a net margin of -33.87% compared to MorphoSys' net margin of -226.79%. Valneva's return on equity of -34.78% beat MorphoSys' return on equity.

Company Net Margins Return on Equity Return on Assets
MorphoSys-226.79% -694.31% -22.55%
Valneva -33.87%-34.78%-13.43%

In the previous week, Valneva had 17 more articles in the media than MorphoSys. MarketBeat recorded 17 mentions for Valneva and 0 mentions for MorphoSys. Valneva's average media sentiment score of 0.28 beat MorphoSys' score of 0.00 indicating that Valneva is being referred to more favorably in the news media.

Company Overall Sentiment
MorphoSys Neutral
Valneva Neutral

Valneva has a consensus price target of $15.00, indicating a potential upside of 67.79%. Given Valneva's stronger consensus rating and higher possible upside, analysts clearly believe Valneva is more favorable than MorphoSys.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
MorphoSys
0 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
0.00
Valneva
0 Sell rating(s)
0 Hold rating(s)
3 Buy rating(s)
0 Strong Buy rating(s)
3.00

Valneva has lower revenue, but higher earnings than MorphoSys. Valneva is trading at a lower price-to-earnings ratio than MorphoSys, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
MorphoSys$238.28M11.99-$205.35M-$3.48-5.45
Valneva$183.52M4.19-$13.25M-$0.98-9.12

18.4% of MorphoSys shares are held by institutional investors. Comparatively, 11.4% of Valneva shares are held by institutional investors. 0.1% of MorphoSys shares are held by insiders. Comparatively, 14.9% of Valneva shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

MorphoSys has a beta of 1.2, meaning that its share price is 20% more volatile than the S&P 500. Comparatively, Valneva has a beta of 1.79, meaning that its share price is 79% more volatile than the S&P 500.

Summary

Valneva beats MorphoSys on 12 of the 16 factors compared between the two stocks.

Get Valneva News Delivered to You Automatically

Sign up to receive the latest news and ratings for VALN and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding VALN and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

VALN vs. The Competition

MetricValnevaMED PRODUCTS IndustryMedical SectorNASDAQ Exchange
Market Cap$768.21M$10.65B$5.81B$10.16B
Dividend YieldN/A1.85%5.69%4.60%
P/E Ratio-9.1221.1174.6225.97
Price / Sales4.1930.58454.4485.61
Price / Cash92.7224.7237.0859.91
Price / Book3.713.5112.156.29
Net Income-$13.25M$210.50M$3.28B$270.77M
7 Day Performance3.35%-0.29%0.98%3.32%
1 Month Performance-4.89%3.81%7.19%6.40%
1 Year Performance28.08%-10.07%63.14%28.24%

Valneva Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
VALN
Valneva
2.7906 of 5 stars
$8.94
-2.6%
$15.00
+67.8%
+31.1%$768.21M$183.52M-9.12700Short Interest ↓
Gap Down
MOR
MorphoSys
N/A$18.96
flat
N/AN/A$2.86B$238.28M-5.45730
HCM
HUTCHMED
2.6398 of 5 stars
$16.11
+0.9%
$28.00
+73.8%
-2.6%$2.79B$630.20M0.001,811News Coverage
Analyst Downgrade
Gap Up
BHC
Bausch Health Cos
4.639 of 5 stars
$7.33
-0.3%
$9.00
+22.9%
+13.7%$2.72B$9.63B28.1720,700
OGN
Organon & Co.
4.6468 of 5 stars
$10.48
+0.9%
$17.33
+65.5%
-47.1%$2.70B$6.40B3.894,000Positive News
KNSA
Kiniksa Pharmaceuticals International
2.2602 of 5 stars
$36.57
+2.4%
$41.17
+12.6%
+52.1%$2.65B$423.24M914.48220Short Interest ↑
GMTX
Gemini Therapeutics
N/A$60.76
+0.9%
N/A+21.0%$2.63BN/A-60.7630
CGON
CG Oncology
2.1878 of 5 stars
$33.69
+1.9%
$53.91
+60.0%
-9.2%$2.52B$1.14M-19.0361Positive News
High Trading Volume
ALVO
Alvotech
3.2787 of 5 stars
$8.16
-2.0%
$14.00
+71.6%
-25.2%$2.51B$491.98M35.481,032Positive News
Short Interest ↓
CPRX
Catalyst Pharmaceuticals
4.9164 of 5 stars
$20.08
-1.0%
$33.20
+65.3%
+4.1%$2.48B$491.73M12.1780Insider Trade
TARS
Tarsus Pharmaceuticals
2.7501 of 5 stars
$56.89
-1.3%
$66.67
+17.2%
+63.1%$2.43B$182.95M-24.4250Positive News
Insider Trade

Related Companies and Tools


This page (NASDAQ:VALN) was last updated on 9/12/2025 by MarketBeat.com Staff
From Our Partners